Azeen James is Vice President, Chief IP Counsel for Biosimilars US at Fresenius Kabi. She joined Fresenius Kabi in 2020, and her work primarily focuses on developing and implementing IP strategies to help Fresenius Kabi provide patients with lower cost biosimilar products in view of patent, regulatory and competitive landscapes. Azeen has more than 26 years of experience in various in-house and outside counsel roles for both biosimilar/generic and innovative pharmaceutical companies.
Azeen is a graduate of Boston University School of Law and holds an M.S. in Organic Chemistry from the University of California, Davis.
